Nama Insights

Omeros (OMER)

Healthcare · Biotechnology · NASDAQ

Omeros (OMER) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.04B, a trailing price-to-earnings ratio of 4.7 and a free-cash-flow yield of -13.1%. Nama's AI scorecard rates it Sell, 4.0 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Sell · 4.0/10
Negative, at the mild end of Sell. As of Nov 20, 2026.
Momentum
Rising · +97.6% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-37.8%
How far the last close sits under the highest price of the past five years.
Market cap$1.04B
Trailing P/E4.7
Price / book—
Price / sales26.4
FCF yield-13.1%
Dividend yield—
Gross margin96.4%
Operating margin-189.5%
Net margin324.9%
Revenue growth (YoY)—
Revenue growth (3-yr annual)—
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta3.0
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

OMER earnings

Next report: Mar 31, 2027 (Q4 2026, EPS estimate $0.25). Beat the EPS estimate in 3 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 16, 2026 -$0.85 -$0.02 -4150.0% $35.93M
Q2 2026 Aug 12, 2026 $0.10 -$0.33 +130.3% $28.53M
Q1 2026 May 13, 2026 $0.57 -$0.39 +246.2% $9.89M
Q4 2025 Mar 31, 2026 $3.14 $2.24 +40.2% $0

OMER analyst price target

Median target $27.50 from 2 analysts, ranging $22.00 – $33.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live OMER data on Nama Insights →

OMER FAQ

Is OMER a buy?
Nama's AI scorecard currently rates Omeros Sell (4.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is OMER's P/E ratio?
Omeros trades at a trailing price-to-earnings ratio of 4.7.
When does OMER report earnings?
Omeros's next scheduled report is on Mar 31, 2027. Analysts expect EPS of $0.25.
What is the OMER price target?
The median analyst price target from 2 analysts is $27.50, with a range of $22.00 – $33.00.
Is OMER Shariah compliant?
Nama's AAOIFI-style screen reads Omeros as Can't Tell. A figure the screen needs is missing, so it can't tell.